Corrigendum: Monitoring and Managing Common Adverse Events with Capivasertib: Practical Steps for US Oncology Teams

Date correction published: 15.04.26

Citation: Oncol AMJ. 2026. https://doi.org/10.33590/oncolamj/43226492

Original publication¹

This infographic, which was originally published on 03.20.26, has been corrected in the ‘hyperglycemia’ row of the ‘Prophylaxis And Management Strategies’ table.

• In the leftmost box in the ‘Incidence’ column of the ‘hyperglycemia’ section, the text originally read “Occurs in 37% (Grade ≥3 in approximately 3%), with a median onset of 15 days.” This has been corrected to: “Occurs in 16.3% (Grade ≥3 in approximately 2.3%), with a median onset of 15 days.” This is to correctly reflect the cited literature.
• In the ‘Step 2: Monitor and Treat’ box of the ‘hyperglycemia’ section, the text originally read: “Days 3–4 of dosing weeks during early cycles, then monthly” has been corrected to: “Monitor fasting glucose on Days 3–4 of dosing weeks during early cycles, then monthly.” This is also to accurately reflect the cited literature.

Reference:

1. Oncol AMJ. 2026; https://doi.org/10.33590/oncolamj/HO8DU459